VRNA
Verona Pharma plc
14.31
USD
This page is just a preview of the data found in TrendSpider’s full version
Verona Pharma plc stock is up 4.61% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 December’s closed higher than November. In the last 6 Unusual Options Trades, there were 1 PUT, 5 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 12 Oct 18:14 | 17 Nov, 2023 | 15.00 | 306 | ||
| 04 Dec 17:22 | 19 Jul, 2024 | 15.00 | 56 | ||
| 04 Dec 17:22 | 19 Jul, 2024 | 15.00 | 56 | ||
| 04 Dec 17:22 | 19 Jul, 2024 | 15.00 | 56 | ||
| 04 Dec 18:03 | 19 Jul, 2024 | 15.00 | 56 | ||
| 04 Dec 18:03 | 19 Jul, 2024 | 15.00 | 56 |
Verona Pharma plc focuses on development and commercialization of therapies for respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Enfentrine is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
